These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

60 related items for PubMed ID: 21565353

  • 1. Analysis of HIV-1 fusion peptide inhibition by synthetic peptides from E1 protein of GB virus C.
    Sánchez-Martín MJ, Hristova K, Pujol M, Gómara MJ, Haro I, Alsina MA, Busquets MA.
    J Colloid Interface Sci; 2011 Aug 01; 360(1):124-31. PubMed ID: 21565353
    [Abstract] [Full Text] [Related]

  • 2. Biophysical investigations of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide.
    Sánchez-Martín MJ, Urbán P, Pujol M, Haro I, Alsina MA, Busquets MA.
    Chemphyschem; 2011 Oct 24; 12(15):2816-22. PubMed ID: 21905195
    [Abstract] [Full Text] [Related]

  • 3. Physicochemical characterization of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide: interaction with model membranes.
    Sánchez-Martín MJ, Cruz A, Busquets MA, Haro I, Alsina MA, Pujol M.
    Int J Pharm; 2012 Oct 15; 436(1-2):593-601. PubMed ID: 22868231
    [Abstract] [Full Text] [Related]

  • 4. Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.
    Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.
    J Phys Chem B; 2009 May 21; 113(20):7383-91. PubMed ID: 19402654
    [Abstract] [Full Text] [Related]

  • 5. Effect of E1(64-81) hepatitis G peptide on the in vitro interaction of HIV-1 fusion peptide with membrane models.
    Sánchez-Martín MJ, Busquets MA, Girona V, Haro I, Alsina MA, Pujol M.
    Biochim Biophys Acta; 2011 Sep 21; 1808(9):2178-88. PubMed ID: 21672514
    [Abstract] [Full Text] [Related]

  • 6. Surface behavior of peptides from E1 GBV-C protein: Interaction with anionic model membranes and importance in HIV-1 FP inhibition.
    Galatola R, Cruz A, Gómara MJ, Prat J, Alsina MA, Haro I, Pujol M.
    Biochim Biophys Acta; 2015 Feb 21; 1848(2):392-407. PubMed ID: 25450346
    [Abstract] [Full Text] [Related]

  • 7. Study of the inhibition capacity of an 18-mer peptide domain of GBV-C virus on gp41-FP HIV-1 activity.
    Haro I, Gómara MJ, Galatola R, Domènech O, Prat J, Girona V, Busquets MA.
    Biochim Biophys Acta; 2011 Jun 21; 1808(6):1567-73. PubMed ID: 21377446
    [Abstract] [Full Text] [Related]

  • 8. Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.
    Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.
    J Med Chem; 2010 Aug 26; 53(16):6054-63. PubMed ID: 20718496
    [Abstract] [Full Text] [Related]

  • 9. Fatty acids can substitute the HIV fusion peptide in lipid merging and fusion: an analogy between viral and palmitoylated eukaryotic fusion proteins.
    Lev N, Shai Y.
    J Mol Biol; 2007 Nov 16; 374(1):220-30. PubMed ID: 17919659
    [Abstract] [Full Text] [Related]

  • 10. Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes.
    Pritsker M, Rucker J, Hoffman TL, Doms RW, Shai Y.
    Biochemistry; 1999 Aug 31; 38(35):11359-71. PubMed ID: 10471286
    [Abstract] [Full Text] [Related]

  • 11. Liposome destabilization induced by synthetic lipopeptides corresponding to envelope and non-structural domains of GBV-C/HGV virus. Conformational requirements for leakage.
    Fernández-Vidal M, Rojo N, Herrera E, Gómara MJ, Haro I.
    Biophys Chem; 2008 Jan 31; 132(1):55-63. PubMed ID: 17988786
    [Abstract] [Full Text] [Related]

  • 12. Modification of FP-HIV activity by peptide sequences of GB virus C: a biophysical approach.
    Domènech O, Ortiz A, Pujol M, Haro I, Muñoz M, Alsina MA, Prat J, Busquets MA, Girona V.
    Biochim Biophys Acta; 2014 May 31; 1838(5):1274-80. PubMed ID: 24530897
    [Abstract] [Full Text] [Related]

  • 13. Synthetic peptides derived from an N-terminal domain of the E2 protein of GB virus C in the study of GBV-C/HIV-1 co-infection.
    Fernández L, Chan WC, Egido M, Gómara MJ, Haro I.
    J Pept Sci; 2012 May 31; 18(5):326-35. PubMed ID: 22438139
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A cyclic GB virus C derived peptide with anti-HIV-1 activity targets the fusion peptide of HIV-1.
    Galatola R, Vasconcelos A, Pérez Y, Cruz A, Pujol M, Alsina MA, Gómara MJ, Haro I.
    Eur J Med Chem; 2014 Oct 30; 86():589-604. PubMed ID: 25218908
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Structural analysis and assembly of the HIV-1 Gp41 amino-terminal fusion peptide and the pretransmembrane amphipathic-at-interface sequence.
    Lorizate M, de la Arada I, Huarte N, Sánchez-Martínez S, de la Torre BG, Andreu D, Arrondo JL, Nieva JL.
    Biochemistry; 2006 Dec 05; 45(48):14337-46. PubMed ID: 17128972
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.